The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Olutasidenib in patients with AML following venetoclax exposure: Final 5-year results from a phase II trial
|
Final 5-year results from a phase II trial (NCT02719574) evaluating the efficacy and safety of olutasidenib in a subgroup of patients with IDH1mut AML following exposure to venetoclax were presented by Jorge Cortes at the SOHO 2024 Annual Meeting.1 A total of 18 adult patients, with median age of 74 years, were included. Patients received olutasidenib 150 mg alone (n = 16) or in combination with standard of care (n = 2). The median duration of prior venetoclax treatment was 5.4 months.1 |
| Key learnings |
| Olutasidenib resulted in ORR/CRc in 50% of all patients previously exposed to venetoclax, including CR/CRh in 39% and CRi in 11% of patients. |
| Of the 18 patients, 16 were R/R to venetoclax. Among these patients, treatment with olutasidenib resulted in ORR/CRc, CR/CRh, and CRi in 44%, 31%, and 13%, respectively. Median time to achieve CR/CRh was 2.1 months and the estimated duration of CR/CRh response was ≥18 months in 80% of patients. |
| In the pivotal cohort of 12 patients with R/R AML post venetoclax, olutasidenib was associated with an ORR/CRc of 50%, CR/CRh of 33%, and CRi of 17%. The median time to achieve CR/CRh was 2.4 months and the estimated duration of CR/CRh response was ≥18 months in 75% of patients. |
| Two patients with CRi with prior venetoclax received maintenance treatment with olutasidenib. Both patients showed improved CR, with a CR duration of 15.7 months and >31.3 months (ongoing), respectively. |
| All patients experienced ≥1 AE, with 89% reporting Grade 3−5 AEs. The most common Grade 3 and 4 AEs were anemia (33%) and neutropenia (22%), respectively. |
| The results suggested that olutasidenib led to deep and durable remissions in patients with IDH1mut AML who were R/R to a prior venetoclax regimen. In those achieving CRi with venetoclax, maintenance with olutasidenib resulted in improved CR. However, the study was limited by its small sample size. |
Abbreviations: AE, adverse event; AML, acute myeloid leukemia; CR, complete remission; CRc, composite CR (CR+CRh+CRi); CRh, CR with partial hematologic recovery; CRi, CR with incomplete hematologic recovery; IDH1mut, IDH1 mutated; ORR, overall response rate; R/R, relapsed/refractory; SOHO, Society of Hematologic Oncology.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?
